Solid Biosciences Looks Like An Obvious Sell Seeking Alpha
An update to Solid’s Phase 1/2 IGNITE DMD study of SGT-001 is good news, but hardly great news, even as analysts give the company unjustified upgrades.
Solid Biosciences Looks Like An Obvious Sell Seeking Alpha
An update to Solid’s Phase 1/2 IGNITE DMD study of SGT-001 is good news, but hardly great news, even as analysts give the company unjustified upgrades.